Saltar al contenido
Merck
Todas las fotos(1)

Documentos

Y0000666

Terazosin for system suitability

CRS, European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Terazosin hydrochloride dihydrate, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride dihydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C19H25N5O4 · HCl · 2H2O
Número de CAS:
70024-40-7
Peso molecular:
459.92
Número MDL:
MFCD00941408
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831082
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

terazosin

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

formato

neat

cadena SMILES

O.O.Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2

Clave InChI

NZMOFYDMGFQZLS-UHFFFAOYSA-N

Información sobre el gen

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Terazosin hydrochloride is a quinazoline derivative. It is a alpha-1-selective adrenoceptor blocking agent. It has been used to treat hypertension, as it helps the blood vessels to relax, expand and improves blood flow.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

It may be used as drug standard stock solution for determination of terazosin hydrochloride dihydrate using potentiometric and fluorimetric techniques.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000622

Terazosin impurity A, European Pharmacopoeia (EP) Reference Standard

1643463

Terazosin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1643474

Terazosin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1643485

Terazosin Related Compound C, United States Pharmacopeia (USP) Reference Standard

Y0000621

Terazosin hydrochloride dihydrate, European Pharmacopoeia (EP) Reference Standard

Y0000665

Terazosin impurity E, European Pharmacopoeia (EP) Reference Standard

Y0000624

Terazosin impurity N, European Pharmacopoeia (EP) Reference Standard

1643452

Terazosin hydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1721

Terazosin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Y0002286

Terazosin for system suitability A, European Pharmacopoeia (EP) Reference Standard

PHR3137

Terazosin Related Compound A, certified reference material, pharmaceutical secondary standard

Pictogramas

Exclamation mark
GHS07

Palabra de señalización

Warning

Frases de peligro

H319

Clasificaciones de peligro

Eye Irrit. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Man Liu et al.
Chirality, 24(12), 1047-1050 (2012-08-14)
The purpose of this study was to elucidate the pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. After a single oral dose of 2-mg terazosin, the plasma concentrations of terazosin enantiomers were measured over the course of 48 h
Gholamreza Mokhtari et al.
Urologia internationalis, 87(1), 19-22 (2011-05-21)
We evaluated the effect of terazosin in the improvement of lower urinary tract symptoms and flank pain in patients with internal ureteral stents. In this double-blind randomized clinical trial, 73 patients with unilateral ureteral stone and hydroureteronephrosis who underwent insertion
Laurel E Ecke et al.
Neuroreport, 23(5), 325-330 (2012-02-18)
The rewarding properties of psychomotor stimulants are traditionally thought to be independent of norepinephrine. Recent findings, however, suggest that local noradrenergic signaling through α1 receptors in the medial prefrontal cortex and the ventral tegmental area - brain regions critically important
M R Yadav et al.
Pharmaceutical biology, 50(4), 439-442 (2011-12-06)
The problem of hypertension has gained enormous proportions in the past decade. Multifactorial etiology and complex pathophysiology of the disease has rendered the treatment of the disease a hard task. Sympathetic nervous system and the renin-angiotensin-aldosterone system are primary contributors
Stephanie C Lazzaro et al.
Learning & memory (Cold Spring Harbor, N.Y.), 17(10), 489-493 (2010-09-28)
Norepinephrine receptors have been studied in emotion, memory, and attention. However, the role of alpha1-adrenergic receptors in fear conditioning, a major model of emotional learning, is poorly understood. We examined the effect of terazosin, an alpha1-adrenergic receptor antagonist, on cued
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico